title: The effect of immunomodulatory treatment on multiple sclerosis fatigue.
abstract: OBJECTIVE
  To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis.
  
  
  METHODS
  Fatigue was measured at baseline and six months using the fatigue impact scale (FIS). Groups (glatiramer acetate and beta interferon) were evaluated for the proportion improved, using Fisher's exact test. Logistic regression analysis assessed the relation between treatment group and improvement and controlled for confounding variables.
  
  
  RESULTS
  Six month paired FIS assessments were available for 218 patients (76% female). Ages ranged between 19 and 61 years, with 86% having relapsing-remitting disease. Glatiramer acetate was used by 61% and beta interferon by 39%. At baseline, total FIS and subscale scores were comparable in the two groups. More patients improved on glatiramer acetate than on beta interferon on total FIS (24.8% v 12.9%, p = 0.033; adjusted odds ratio = 2.36, 95% confidence interval 1.03 to 5.42), and on physical (28.6% v 14.1%, p = 0.013) and cognitive subscales (21.1% v 10.6%, p = 0.045). Logistic regression analysis confirmed the association between glatiramer acetate use and improved fatigue, after accounting for baseline group differences.
  
  
  CONCLUSIONS
  The odds of reduced multiple sclerosis fatigue were around twice as great with glatiramer acetate treatment as with beta interferon. Confirmation of this result is required.
authors.affiliation: Department of Clinical Neurosciences, University of Calgary, Alberta, Canada. lmetz@ucalgary.ca
authors.forename: L M
authors.initials: LM
authors.lastname: Metz
authors.forename: S B
authors.initials: SB
authors.lastname: Patten
authors.forename: C J
authors.initials: CJ
authors.lastname: Archibald
authors.forename: J I
authors.initials: JI
authors.lastname: Bakker
authors.forename: C J
authors.initials: CJ
authors.lastname: Harris
authors.forename: D G
authors.initials: DG
authors.lastname: Patry
authors.forename: R B
authors.initials: RB
authors.lastname: Bell
authors.forename: M
authors.initials: M
authors.lastname: Yeung
authors.forename: W F
authors.initials: WF
authors.lastname: Murphy
authors.forename: C A
authors.initials: CA
authors.lastname: Stoian
authors.forename: K
authors.initials: K
authors.lastname: Billesberger
authors.forename: L
authors.initials: L
authors.lastname: Tillotson
authors.forename: S
authors.initials: S
authors.lastname: Peters
authors.forename: D
authors.initials: D
authors.lastname: McGowan
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D005221:Fatigue / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta